Related Experiment Video
Updated: Aug 23, 2026
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
Published on: May 4, 2012
Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods
Jin Zhang1,2, Rong Li1, Xueqin Tan1
1North Sichuan Medical College, Nanchong, Sichuan, China.
Abstract:
Recent advancements in cancer immunotherapy have highlighted glypican-3 (GPC3) as a prominent target for treating hepatocellular carcinoma (HCC). However, approximately 10% to 30% of HCC patients exhibit low or absent GPC3 expression on the surface of tumor cells, which limits the feasibility of GPC3-targeted therapies. Consequently, it is essential for patients to undergo pre-diagnostic assessments of GPC3 expression in tumor cells to evaluate their suitability for GPC3-directed therapy. Although various methods have been developed to specifically detect GPC3 as a biomarker for treatment and prognosis, the diagnostic approaches currently employed in clinical studies remain relatively limited. Here, we provide a comprehensive overview of the clinical development of GPC3-targeted therapeutics, clinical trials in GPC3-positive HCC, and current methods for detecting GPC3 expression, highlighting their advantages and limitations. Furthermore, we explore the potential of integrating targeted therapy with various GPC3 detection modalities tailored to different pathological stages. This integration not only provides insights into the selection of effective methods for detecting GPC3 expression but also has the potential to significantly improve the clinical outcomes of patients with liver cancer. By simultaneously assessing the advantages and disadvantages of these methods, this review aims to establish a theoretical foundation for the clinical selection of appropriate GPC3 detection strategies for targeted therapy.
Insights
Glypican-3 (GPC3) is a key target for liver cancer immunotherapy, but low expression limits treatment. This review covers GPC3-targeted therapies, detection methods, and their integration for better patient outcomes.
Area of Science:
- Hepatocellular Carcinoma Research
- Cancer Immunotherapy
- Biomarker Discovery
Background:
- Glypican-3 (GPC3) is a promising target for hepatocellular carcinoma (HCC) immunotherapy.
- Limited GPC3 expression in 10-30% of HCC patients restricts GPC3-targeted therapy efficacy.
- Pre-diagnostic assessment of GPC3 expression is crucial for patient selection.
Purpose of the Study:
- To provide a comprehensive overview of GPC3-targeted therapeutics and clinical trials in GPC3-positive HCC.
- To review current GPC3 detection methods, analyzing their advantages and limitations.
- To explore the integration of GPC3 detection modalities with targeted therapy for improved liver cancer treatment.
Main Methods:
- Literature review of GPC3-targeted therapeutics and clinical trials.
- Analysis of existing GPC3 detection methods for HCC.
- Exploration of integrating diagnostic strategies with therapeutic approaches.
Main Results:
- GPC3 is a significant biomarker for HCC, with ongoing clinical development of targeted therapies.
- Various methods exist for GPC3 detection, each with specific strengths and weaknesses.
- Integrating detection methods with targeted therapy can optimize treatment selection and patient outcomes.
Conclusions:
- Effective selection of GPC3 detection strategies is vital for successful targeted therapy in HCC.
- Further research into integrated diagnostic and therapeutic approaches can enhance clinical outcomes for liver cancer patients.
- This review establishes a foundation for choosing appropriate GPC3 detection methods for targeted HCC treatment.
